First Tracks Biotherapeutics Targets About $200 Million in Placement

First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX) agreed to sell about 6.11 million common shares to institutional investors at $32.75 each, with the placement expected to generate about $200 million in gross proceeds. John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.

BeCrypto News shows a short excerpt and links to the publisher. The full report belongs to TokenPost.